Jode Goodridge

420 total citations · 1 hit paper
20 papers, 285 citations indexed

About

Jode Goodridge is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Jode Goodridge has authored 20 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Jode Goodridge's work include CAR-T cell therapy research (20 papers), Immune Cell Function and Interaction (11 papers) and CRISPR and Genetic Engineering (4 papers). Jode Goodridge is often cited by papers focused on CAR-T cell therapy research (20 papers), Immune Cell Function and Interaction (11 papers) and CRISPR and Genetic Engineering (4 papers). Jode Goodridge collaborates with scholars based in United States, Norway and Sweden. Jode Goodridge's co-authors include Bahram Valamehr, Tom Lee, Ryan Bjordahl, Brian Groff, Svetlana Gaidarova, Karl‐Johan Malmberg, Greg Bonello, Sajid Mahmood, Robert Blum and Bruce Walcheck and has published in prestigious journals such as The Lancet, Blood and Cancer Research.

In The Last Decade

Jode Goodridge

20 papers receiving 278 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial

2025 42 citations Armin Ghobadi, Veronika Bachanová et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jode Goodridge United States	8	240	187	83	42	28	20	285
Greg Bonello United States	6	181 0.8×	152 0.8×	63 0.8×	33 0.8×	14 0.5×	13	214
Lorena Pérez-Amill Spain	7	150 0.6×	131 0.7×	41 0.5×	20 0.5×	33 1.2×	11	200
Yaara Ohayon United States	4	309 1.3×	231 1.2×	73 0.9×	54 1.3×	12 0.4×	4	335
Katherine A. Freitas United States	2	179 0.7×	116 0.6×	140 1.7×	34 0.8×	15 0.5×	4	267
Yue Tan China	6	151 0.6×	45 0.2×	39 0.5×	62 1.5×	20 0.7×	10	171
Licui Jiang China	6	182 0.8×	150 0.8×	37 0.4×	34 0.8×	17 0.6×	8	212
Kayla Reid United States	8	181 0.8×	56 0.3×	58 0.7×	53 1.3×	16 0.6×	17	196
Jinlong Xu China	6	139 0.6×	42 0.2×	37 0.4×	51 1.2×	19 0.7×	16	177
Myo Htut United States	8	144 0.6×	53 0.3×	70 0.8×	16 0.4×	75 2.7×	13	172
Nathaniel Dasyam New Zealand	5	305 1.3×	126 0.7×	104 1.3×	83 2.0×	12 0.4×	8	336

Countries citing papers authored by Jode Goodridge

Since Specialization

Citations

This map shows the geographic impact of Jode Goodridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jode Goodridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jode Goodridge more than expected).

Fields of papers citing papers by Jode Goodridge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jode Goodridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jode Goodridge. The network helps show where Jode Goodridge may publish in the future.

Co-authorship network of co-authors of Jode Goodridge

This figure shows the co-authorship network connecting the top 25 collaborators of Jode Goodridge. A scholar is included among the top collaborators of Jode Goodridge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jode Goodridge. Jode Goodridge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghobadi, Armin, Veronika Bachanová, Krish Patel, et al.. (2025). Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. The Lancet. 405(10473). 127–136. 42 indexed citations breakdown →

Hancock, Bryan, Brian Groff, Yijia Pan, et al.. (2024). Abstract 3618: High-avidity BCMA CAR and high-affinity, non-cleavable CD16 Fc receptor incorporated in off-the-shelf CAR T cells promote multi-antigen targeting and durable anti-tumor cytotoxicity in the treatment of multiple myeloma. Cancer Research. 84(6_Supplement). 3618–3618. 1 indexed citations

Hammer, Quirin, Karlo Perica, Rina M. Mbofung, et al.. (2024). Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell stem cell. 31(9). 1376–1386.e8. 18 indexed citations

Drake, Charles G., Alex Garcia, Chia‐Wei Chang, et al.. (2022). 326 Off-the-shelf iPSC-derived CAR-T cells targeting KLK2 demonstrate prolonged tumor control and survival in xenograft models of prostate cancer. Regular and Young Investigator Award Abstracts. A343–A343. 2 indexed citations

Hammer, Quirin, Karlo Perica, Rina M. Mbofung, et al.. (2022). Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection. Blood. 140(Supplement 1). 1165–1166. 5 indexed citations

Pan, Yijia, Brian Groff, Rina M. Mbofung, et al.. (2022). Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy. Blood. 140(Supplement 1). 4547–4548. 7 indexed citations

Dhakal, Binod, Jesús G. Berdeja, Lilly Wong, et al.. (2022). Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma. Blood. 140(Supplement 1). 4586–4587. 41 indexed citations

Mahmood, Sajid, Yijia Pan, Bryan Hancock, et al.. (2022). Abstract 4190: Combining dual CAR iPSC-derived immune cells with antibody for multi-antigen targeting to overcome clonal resistance in multiple myeloma. Cancer Research. 82(12_Supplement). 4190–4190. 1 indexed citations

Chan, Szeman Ruby, Yanni Zhu, Andrew S. Gilder, et al.. (2022). FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma. Blood. 140(Supplement 1). 4560–4561. 18 indexed citations

10.

Mbofung, Rina M., Yijia Pan, Sushil Devkota, et al.. (2022). iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma. Blood. 140(Supplement 1). 7388–7389. 2 indexed citations

11.

Mahmood, Sajid, Yijia Pan, Bryan Hancock, et al.. (2021). Dual Chimeric Antigen Receptor Approach Combining Novel Tumor Targeting Strategies Circumvents Antigen Escape in Multiple Myeloma. Blood. 138(Supplement 1). 1718–1718. 9 indexed citations

12.

Mbofung, Rina M., Yijia Pan, Brian Groff, et al.. (2021). Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection. Blood. 138(Supplement 1). 2795–2795. 2 indexed citations

13.

Pan, Yijia, Brian Groff, Rina M. Mbofung, et al.. (2021). A Novel Stealth Strategy That Activates Adoptively Transferred Allogeneic Immune Cells and Avoids Rejection for Off-the-Shelf Cell-Based Cancer Therapy. Blood. 138(Supplement 1). 4800–4800. 1 indexed citations

14.

Goodridge, Jode, Ryan Bjordahl, Sajid Mahmood, et al.. (2021). Abstract 1550: FT576 path to first-of-kind clinical trial: translation of a versatile multi-antigen specific off-the-shelf NK cell for treatment of multiple myeloma. Cancer Research. 81(13_Supplement). 1550–1550. 7 indexed citations

15.

Goodridge, Jode, Ryan Bjordahl, Sajid Mahmood, et al.. (2020). FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma. Blood. 136(Supplement 1). 4–5. 34 indexed citations

16.

Goodridge, Jode, Ryan Bjordahl, Chia‐Wei Chang, et al.. (2020). Abstract 2216: Combinational strategy targeting B cell malignancy using iPSC engineered CAR-NK (FT596) and CAR-T cell (FT819) platforms with therapeutic antibody to achieve an effective deep and durable response. Cancer Research. 80(16_Supplement). 2216–2216. 1 indexed citations

17.

Bjordahl, Ryan, Zhu Huang, Paul Rogers, et al.. (2019). Abstract 3191: FT516, an off-the-shelf engineered NK cell therapeutic product for universal anti-tumor targeting strategy in combination with monoclonal antibodies. Cancer Research. 79(13_Supplement). 3191–3191. 1 indexed citations

18.

Goodridge, Jode, Sajid Mahmood, Zhu Huang, et al.. (2019). FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies. Blood. 134(Supplement_1). 301–301. 66 indexed citations

19.

Goodridge, Jode, Sajid Mahmood, Zhu Huang, et al.. (2019). Abstract 3207: Preclinical development of first-of-kind dual-targeted off-the-shelf CAR-NK cell product with engineered persistence for an effective treatment of B cell malignancies. Cancer Research. 79(13_Supplement). 3207–3207. 1 indexed citations

20.

Bjordahl, Ryan, Svetlana Gaidarova, Jode Goodridge, et al.. (2019). FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma. Blood. 134(Supplement_1). 3214–3214. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact